Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates

Copenhagen, Denmark, April 20, 2026 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of first- and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, today announced multiple clinical and regulatory updates for the Company’s pipeline of first- and best-in-class ADCs. ADCE-T02 has advanced into cohort expansion portion […]